Alterations of Spermatozoa Proteomic Profile in Men with Hodgkin’s Disease Prior to Cancer Therapy

• Main Authors: Ana D. Martins, Ashok Agarwal, Saradha Baskaran, Peter Natesan Pushparaj, Gulfam Ahmad, Manesh Kumar Panner Selvam
• Format: Article
• Language: English
• Published: Korean Society for Sexual Medicine and Andrology 2020-10-01
• Series: The World Journal of Men's Health
• Subjects: hodgkin disease; infertility; mass spectrometry; proteomics; spermatozoa; transferrin

Purpose: Hodgkin’s disease (HD) is a type of cancer affecting men in the reproductive age with potential consequences on their fertility status. This study aims to analyze sperm parameters, alterations in proteomic profiles and validate selected protein biomarkers of spermatozoa in men with HD undergoing sperm banking before cancer therapy. Materials and Methods: Semen analysis was carried out in healthy fertile donors (control, n=42), and patients diagnosed with HD (patients, n=38) before cancer therapy. We compared proteomic profiles of spermatozoa from donors (n=3) and patients (n=3) using LTQ-Orbitrap Elite hybrid MS system. Results: A total of 1,169 proteins were identified by global proteomic in both groups. The ingenuity pathway analysis revealed that differentially expressed proteins involved in capacitation, acrosome reaction, binding of sperm to the zona pellucida, sperm motility, regulation of sperm DNA damage, and apoptosis were significantly downregulated in HD patients. Validation of proteins implicated in sperm fertility potential by Western Blot demonstrated that peroxiredoxin 2 (PRDX 2) was underexpressed (p=0.015), and transferrin (p=0.045) and SERPIN A5 (p=0.010) protein levels were overexpressed in spermatozoa of men with HD. Conclusions: Findings of this study indicates that the key proteins involved in sperm fertility potential are significantly altered in men with HD, which provides substantial explanation for the observed low sperm quality in HD subjects prior to cancer therapy. Furthermore, our results suggest PRDX 2, transferrin and SERPIN A5 as possible candidate proteins for assessing sperm quality in HD patients prior to cancer therapy.